Xiangrui Meng - The First Affiliated Hospital, Zhengzhou University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Camrelizumab Combined with Apatinib As Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase 2 Trial

Xiangrui Meng,Yu Qi,Zhengzheng Shan, Yang,Qingxia Fan,Feng Wang

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

A Phase Ib/II Study of Fruquintinib in Combination with SOX and Toripalimab As First-Line Treatment for Advanced Metastatic Gastric/gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Xiangrui Meng,Zhengzheng Shan,Lulu Guan,Xin Dao,Qingxia Fan,Feng Wang

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 335-335

引用0浏览0引用

Camrelizumab Plus Apatinib after Progression on Immune Checkpoint Inhibitors in Patients with Advanced Esophageal Squamous Cell Carcinoma (CAP 02 Re-challenge): A Single-Arm Multicenter, Phase II Trial

Xiangrui Meng,Junsheng Wang,Jin Xia,Tao Wu,Zhiquan Luo, Yong-Gui Hong,Ping Lu, Yanzhen Guo, Yinghua Ji,Min Zhang, Liuzhong Yang, Peng Cheng,Wenchang Liang,Zhengzheng Shan, Qingxia Fan,Feng Wang

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 364-364

引用0浏览0引用

A Single-Arm, Open-Label Phase II Clinical Trial of SHR-1210 (camrelizumab) in Combination with Nimotuzumab in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Feng Wang,Jin Xia,Xiangrui Meng, Yinghua Ji,Xiuli Yang, Yong-Gui Hong,Junsheng Wang, Donghai Cui,Zhiquan Luo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Efficacy and Safety of Camrelizumab Plus Apatinib in Patients with Advanced Esophageal Squamous Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors (CAP 02 Re-challenge): a Single-Arm, Phase II Study

Xiangrui Meng,Junsheng Wang,Jin Xia,Tao Wu,Zhiquan Luo,Yonggui Hong,Ping Lu,Yanzhen Guo,Yinghua Ji,Min Zhang,Liuzhong Yang, Peng Cheng,Wenchang Liang,Zhengzheng Shan,Yue Zhou,Mingyue Wang,Taiying Lu, Min Song,Hong Zong,Lijie Song, Wenkang Wang,Lulu Guan, Yanke Li, Jianxiang Xing, Siyuan Xing, Han Wu, Jingwen Chu,Xi Luo,Yao Lu,Dao Xin, Aijia Li, Binghua Jiang, Shenglei Li, Guozhong Jiang,Qingxia Fan, Feng Zhao,Rongrong Zheng, Wenqing Zhu, Zhiguo Hou, Yun Jia,Feng Wang

EUROPEAN JOURNAL OF CANCER (2024)

引用0浏览0WOS引用

Neoadjuvant Camrelizumab Followed by Concurrent Camrelizumab Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Single-Arm, Phase II Study

Yinliang Sheng,Xiangrui Meng,Chunyang Zhang,Zhengzheng Shan,Feng Li,Bin Wu,Mengli Xu, Aijia Li,Lulu Guan, Lidong Chen, Shuzhen Sun,Yihui Ma,Taiying Lu,Song Zhao,Qingxia Fan,Yu Qi,Feng Wang

Journal of Thoracic Diseaseno. 8 (2024): 5337-5347

引用0浏览0WOS引用

Reactivation of Mutant P53 in Esophageal Squamous Cell Carcinoma by Isothiocyanate Inhibits Tumor Growth

Lulu Guan,Yalan Yang,Yao Lu,Yu Chen,Xi Luo,Dao Xin,Xiangrui Meng,Zhengzheng Shan,Guozhong Jiang,Feng Wang

FRONTIERS IN PHARMACOLOGY (2023)

引用0浏览0WOS引用

Exploration of Immune Tolerance and Treatment for Esophageal Cancer

XING Siyuan,FAN Qingxia,SHAN Zhengzheng,MENG Xiangrui,WANG Feng

Zhongliu Fangzhi Yanjiuno. 12 (2023): 1174-1179

引用0浏览0引用

A First-in-human, Open-Label, Dose-Escalation and Dose-Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/pharmacodynamics, and Antitumor Activity of QL1604, a Humanized Anti–pd-1 Mab, in Patients with Advanced or Metastatic Solid Tumors

Zhiyu Huang,Yanjun Xu,Wei Hong,Lei Gong,Kaiyan Chen,Jing Qin,Fajun Xie,Feng Wang,Xin Tian,Xiangrui Meng, Wenlei Feng,Lingyan Li,Baihui Zhang,Xiaoyan Kang,Yun Fan

FRONTIERS IN IMMUNOLOGY（2023）

引用0浏览0WOS引用

Camrelizumab Plus Apatinib for Immunochemotherapy-Treated Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of Cohort 2 in CAP 02 Study

Feng Wang,Junsheng Wang,Xiangrui Meng,Zhiquan Luo,Jin Xia,Yong-Gui Hong,Ping Lu,Yinghua Ji,Zheng-Zheng Shan, Qingxia Fan

Journal of clinical oncologyno. 4_suppl (2023): 384-384

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn